- Home
- GNS vs CCEL Comparison
GNS vs CCEL Comparison
Compare GNS & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | CCEL |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Managed Health Care |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 32.7M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GNS | CCEL |
|---|---|---|
| Price | $0.12 | $5.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 11.1K |
| Earning Date | 09-28-2026 | 10-09-2026 |
| Dividend Yield | ★ 155.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | $127.02 | N/A |
| Revenue Next Year | $36.19 | N/A |
| P/E Ratio | ★ N/A | $22.54 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.12 | $2.72 |
| 52 Week High | $1.06 | $5.45 |
Technical Indicators
Market Signals| Indicator | GNS | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 62.09 |
| Support Level | $0.12 | $3.16 |
| Resistance Level | $0.14 | N/A |
| Average True Range (ATR) | 0.01 | 0.41 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 6.18 | 81.34 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.